EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Direct‐to‐participant investigational medicinal product supply in clinical trials in Europe: Exploring the experiences of sponsors, site staff and couriers

Amos J de Jong iD, Yared Santa-Ana-Tellez, Mira G P Zuidgeest, Renske J Grupstra, Fatemeh Jami, Anthonius de Boer iD, Helga Gardarsdottir iD, Trials@Home Consortium

British Journal of Clinical Pharmacology · 2023

DOI: 10.1111/bcp.15850 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Amos J de Jong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlan…. Hauptthemen laut MEDLINE: Community Pharmacy Services, Pharmacies. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: EU/EFPA Innovative Medicines Initiative Joint Undertaking Trials@Home.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Insights into the current practice of direct‐to‐participant (DtP) supply of investigational medicinal product (IMP) in the context of clinical trials conducted in Europe are needed, as regulations are unharmonized. This study is set out to explore how DtP IMP supply has been employed in Europe and what the advantages and disadvantages and barriers and facilitators of its implementation are.

Methods

We conducted semi‐structured interviews with representatives from sponsor companies, courier services and site study staff involved in the IMP dispensing and delivery process in Europe. Interviews were conducted between May and November 2021, and data were analysed following thematic analysis.

Results

Sixteen respondents participated in one of the 12 interviews. Respondents had experience with different models of DtP IMP supply including shipment from the investigative site, a central pharmacy (a depot under the control of a pharmacist) and a local pharmacy—aiming to reduce trial participation burden. The respondents indicated that investigative site‐to‐participant shipment is not affected by regulatory barriers, but could burden site staff. Shipment from central locations was considered most efficient, but possible regulatory barriers related to maintaining participants' privacy and investigator oversight were identified. The respondents indicated that the involvement of local pharmacies to dispense IMP can be considered when the IMP is authorized.

Conclusions

Several DtP IMP supply models are implemented in clinical trials conducted in Europe. In this study, three main DtP IMP models were identified, which can be referenced when describing these approaches for regulatory approval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Community Pharmacy ServicesPharmaciesHumansEuropePharmacistsClinical Trials as Topic

Stichwörter der Autor:innen

DtPdecentralized clinical trialdirect-to-participantdirect-to-patienthome deliverypatient-centric

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Strategic Advice R&D Quality Assurance, AstraZeneca, Cambridge, UK.
  • Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
  • Department of Clinical Pharmacy, Division Laboratory and Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland.

ORCID-Profile: Amos J de Jong, Anthonius de Boer, Helga Gardarsdottir

Förderung

  • EU/EFPA Innovative Medicines Initiative Joint Undertaking Trials@Home

Zitieren

APA

de Jong, A. J., Santa-Ana-Tellez, Y., Zuidgeest, M. G. P., Grupstra, R. J., Jami, F., de Boer, A., Gardarsdottir, H., & Trials@Home Consortium (2023). Direct‐to‐participant investigational medicinal product supply in clinical trials in Europe: Exploring the experiences of sponsors, site staff and couriers. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15850

Vancouver

de Jong AJ, Santa-Ana-Tellez Y, Zuidgeest MGP, Grupstra RJ, Jami F, de Boer A, et al. Direct‐to‐participant investigational medicinal product supply in clinical trials in Europe: Exploring the experiences of sponsors, site staff and couriers. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15850

BibTeX
@article{deJong2023,
  author = {de Jong, Amos J and Santa-Ana-Tellez, Yared and Zuidgeest, Mira G P and Grupstra, Renske J and Jami, Fatemeh and de Boer, Anthonius and Gardarsdottir, Helga and Trials@Home Consortium, Trials@Home Consortium},
  title = {Direct‐to‐participant investigational medicinal product supply in clinical trials in Europe: Exploring the experiences of sponsors, site staff and couriers},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1111/bcp.15850}
}
Kostenlos starten →